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Abstract
Olive oil is considered to be one of the most healthy dietary fats. There are, however, several types of olive oil present on the market. 
With the data at present available, the most healthy of them is the virgin olive oil (VOO), rich in phenolic compounds. On November 
2011, the European Food Safety Authority (EFSA) released a claim concerning the benefits of the daily ingestion of olive oil rich in 
phenolic compounds, such as the VOO. In this review, we will summarize the work which have provided scientific evidence of the 
benefits of VOO consumption over other type of edible oils even olive oils. Data from randomized, controlled human studies, will 
be presented. This type of studies are able to provide evidence of Level I which is that required for performing nutritional recom-
mendations at population level.
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Resumen
Se considera al aceite de oliva una de las grasas más saludables de la dieta. Hay, sin embargo, varios tipos de aceite de oliva 
presentes en el mercado. Con los datos actualmente disponibles, el más saludable de ellos es el aceite de oliva virgen (AOV), rico 
en compuestos fenólicos. En noviembre de 2011, la Autoridad Europea de Seguridad Alimentaria (EFSA) publicó un declaración 
acerca de los beneficios de la ingesta diaria de aceite de oliva rico en compuestos fenólicos, como el VOO. En esta revisión, 
vamos a resumir el trabajo que ha proporcionado la evidencia científica de los beneficios del consumo de AOV sobre otro tipo de 
aceites comestibles e incluso sobre los otros tipos de aciete de oliva. Presentamos, asimismo, los datos de estudios aleatorizados 
y controlados en humanos. Este tipo de estudios proporcionan evidencia de nivel I, que es el nivel requerido para ofrecer reco-
mendaciones nutricionales a nivel poblacional.
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Introduction
Olive oil is the primary source of fat in the Mediterranean 
diet which is associated with a low mortality for cardio-
vascular disease1. A large body of knowledge exists pro-
viding evidence of the benefits of olive oil consumption 
on secondary end points for cardiovascular disease2. On 
November 2004, the Federal Drug Administration (FDA) 
of the U.S.A permitted a claim on olive oil labels concer-
ning: “the benefits on the risk of coronary heart disease 
of eating about 2 tablespoons (23 grams) of olive oil daily, 
due to the monounsaturated fat (MUFA) in olive oil” 3. Re-
cently, results of large EPIC cohorts have reported an in-
verse relationship between olive oil consumption and co-
ronary heart disease (CHD) mortality and incidence4,5. An 
inverse relationship between olive oil consumption and 
stroke risk in women has been reported in the Three-City 
Study6.  
Olive oil has major and minor components. The former 
are the fatty acids, of which the monounsaturated fatty 
acid (MUFA), the oleic acid, represents from 55% to 83% 
of the total fatty acids7.The minor components of olive oil 
constitute from 1% to 2% of the total content of an olive 
oil and are classified as: 1) the unsaponifiable fraction, 
which can be extracted with solvents after the saponi-
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fication of the oil and contains squalene and other tri-
terpenes, sterols, tocopherol, and pigments, and 2) the 
soluble fraction that includes the phenolic compounds, 
the complex forms called polyphenols. Phenolic com-
pounds are present as simple phenols or conjugated 
forms (Figure 1). Tyrosol (Tyr), hydroxytyrosol (OHTyr), 
and their secoiridoid derivatives make up around 90% 
of the total phenolic content of a virgin olive oil. Pheno-
lic compounds from olive oil are the most studied and 
best known components in terms of their benefits for 
health7. The content of the minor components of an olive 
oil varies, depending on the cultivar, climate, ripeness 
of the olives at harvesting, and the processing system 
employed to produce the olive oil. Olive oils currently 
present on the market are: extra-virgin, virgin, olive oil 
(UE, 1991), or pomace (also called orujo) olive oil. Virgin 
olive oils (VOOs) are those obtained from the fruit of the 
olive tree solely by mechanical or other physical means 
under conditions that do not lead to alteration in the oil. 
Extra-VOOs are VOOs with a free acidity, expressed as 
g of oleic acid/100 g of olive oil, less than 0.8 g. VOOs 
with an acidity greater than or equal to 3.3 (International 
Olive Oil Council Regulation/ T.15/NC.n3.Rev2.Nov24, 
2006) or greater than 2 in Europe (European Regulation 
N. 1513/0) are submitted to a refining process in which 
some components, mainly phenolic compounds, and to 
a lesser degree squalene, are lost8. By mixing virgin and 
refined olive oil an ordinary olive oil (olive oil, UE 1991) 
is produced and marketed. After VOO production, the 
rest of the olive drupe and seed is submitted to a refining 
process, resulting in pomace olive oil, to which a certain 
quantity of VOO is added before marketing8. 
Here, we will summarize the key work which has provi-
ded evidence of the benefits of VOO consumption over 
other type of edible oils even olive oils. We will focus on 
data from randomized, controlled human studies, which 
are those capable to provide the evidence of Level I9. 
On the basis of the Evidence-Based Medicine, evidence 
of Level I is which is required for performing nutritional 
recommendations at population level. 
Metabolic disposition of olive oil 
phenolic compounds in humans from 
real-life doses of natural olive oils.
One of the prerequisites for assessing the physiological 
significance of olive oil phenolic compounds is the ability 
to determine their bioavailability in human beings. Tyr and 
OHTyr are absorbed by humans from olive oil in a dose-
dependent manner with the phenolic content of the olive 
oil administered both after a single dose or after sustained 
olive oil consumption10,11. This implies an accumulation in 
the body even from moderate doses of olive oil (25 mL/d) 
which are lower than the traditional daily dietary intake in 
Mediterranean countries (30-50g/day). The bioavailability 
of OHTyr, however, has been shown to change largely 
depending on the matrix in which the phenolic com-
pounds are administered, the most effective matrix being 
the olive oil12. Around 98% of Tyr and OHTyr are present 
in plasma and urine in conjugated forms, glucuronocon-
jugates or sulfates. This fact indicates the existence of an 
extensive first-pass intestinal/hepatic metabolism of the 
ingested primary forms13. 
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Figure 1: Structures of the major phenolic compounds identified in olives and olive oil. A, hydroxytyrosol; B, tyrosol;  C, oleuropein glucoside; D, dialdehydic form of 
oleuropein (SID-1); E, ligstroside (SID-2); F, aglycone form of oleuropein glucoside (SID-3); G, ligstroside SID-4; H, lignanes (+)-pinoresinol; I: (+)-1-acetoxypinoresinol.
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Lipoproteins and 
Lipoprotein Oxidation 
The replacement of saturated fatty acids (SFA) by oils 
enriched in MUFA versus polyunsaturated fatty acids 
(PUFA) had similar effects on lowering total and low den-
sity lipoproteins (LDL) cholesterol. The PUFA-enriched oil 
had a slight triglyceride lowering effect, and there was 
an increase in HDL cholesterol after MUFA consumption 
in some studies14. There is, however, an issue in which 
MUFA consumption prevails over the PUFA one: the li-
poprotein oxidation. Oleate-rich LDL are less susceptible 
against oxidation than linoleate-rich particles. This is due 
to the fact that PUFAs are the key substrate for lipid pe-
roxidation whose propagation chain is going on via the 
double bonds of the fatty acid15. From 14 studies com-
paring the resistance of LDL to oxidation only in 2 of them 
did MUFA-rich diets not promote a higher resistance of 
LDL to oxidation than PUFA-rich ones16.
Oxidation of the lipid part, or directly of the apolipoprotein 
(apo) B, of the LDL leads to a change in the lipoprotein 
conformation by which the LDL is better able to enter 
into the monocyte/macrophage system of the arterial 
wall, and develop the atherosclerotic process17. Oxidized 
LDL has been shown to be independently associated 
with 10-year coronary artery disease (CAD) events in the 
general population, and improved the reclassification ca-
pacity of Framingham-derived CAD risk functions18. 
Phenolic compounds present in VOO have proven to be 
protective against LDL oxidation. On November 2011, the 
European Food Safety Authority (EFSA) released a claim 
concerning the benefits of the daily ingestion of olive oil 
rich in phenolic compounds, such as the virgin olive oil. 
The Panel considers that in order to bear the claim, 5 mg 
of OHTyr and its derivatives (e.g. oleuropein complex and 
Tyr) in olive oil should be consumed daily. These quanti-
ties, if provided by moderate amounts of olive oil, can be 
easily consumed in the context of a balanced diet19. Here 
we will revise the main studies which supported this EFSA 
claim concerning the benefits of phenolic compound-rich 
olive oil such as VOO.
Human studies on the postprandial 
effect of olive oil on oxidative stress 
and oxidative damage 
After meals, particularly those rich in fats, a postprandial 
hyperlipemia and hyperglycemia occurs, which is linked 
to oxidative stress. Although fasting hyperlipidemia is 
considered an important risk for cardiovascular disease, 
postprandial serum lipid levels have been found to corre-
late more closely to cardiovascular diseases than fasting 
lipids20. Activation of peroxisome proliferator-activated 
receptor-α (PPARα) suppresses postprandial lipidemia 
through fatty acid oxidation in enterocytes21. A functional 
olive oil enriched with its own phenolic compounds has 
shown to enhance the gene expression of PPARα in mo-
nonuclear cells of pre- and stage I hypertensive patients22.
Several data on the effect of olive oil rich in phenolic 
compounds, such as VOO, on the postprandial oxidati-
ve stress have been reported. They are, however, diffi-
cult to compare because some studies do not mention 
whether or not postprandial lipemia and/or hyperglycemia, 
which could lead to oxidative stress, occur after olive oil 
ingestion, while in other studies neither hyperlipemia nor 
hyperglycemia occur at postprandial state after the olive 
oil ingestion7, 8 .The ingestion of a 25 mL olive oil dose did 
not promote postprandial oxidative stress, with indepen-
dence of the phenolic content of the olive oil, whereas 
single doses of 40 mL and 50 mL did8. With olive oil doses 
at which oxidative stress occurs, data from randomized, 
cross-over, controlled studies in humans showed: i) an in-
crease in the serum antioxidant capacity after VOO inges-
tion, but not after ordinary olive oil, in comparison with corn 
oil, suggesting a role for the phenolic compounds of the 
VOO; and ii) the phenolic content of an olive oil modulates 
the degree of lipid and LDL oxidation, the lipid oxidative 
damage being lower after high- than after low-phenolic 
content olive oil8. In comparison with sunflower oil, meals 
submitted to a deep frying with olive oils rich in phenolic 
compounds, both natural and added, have shown to re-
duce the postprandial oxidative stress in obese people23. 
Recently, it has been described that food fried in extra-
virgin olive oil improves postprandial insulin response, an 
oxidative stress associated phenomenae, in obese, insu-
lin-resistant women24.
Human studies of the sustained effect 
of olive oil on oxidative stress and oxi-
dative damage 
Controversial results have been obtained in short sample 
size (n<30) human randomized controlled studies perfor-
med up to now on the effect of sustained doses of olive 
oil phenolic compounds on oxidative stress7, 8. Extensive 
differences existed among the studies in the experimen-
tal. design, control of diet, sample population, age of the 
participants, measurement or not of markers of the com-
pliance of the intervention, as well as in the sensitivity and 
specificity of the oxidative stress biomarkers evaluated. 
This fact could explain the differences of results obser-
ved among studies.
The results of the EUROLIVE study, however, have provi-
ded final evidence of the in vivo protective role of pheno-
lic compounds from olive oil on lipid oxidative damage in 
humans, at real-life olive oil doses10. The EUROLIVE (The 
effect of olive oil consumption on oxidative damage in Eu-
ropean populations) study was a large, crossover, multi-
centre, clinical trial performed in 200 individuals from five 
European countries. Participants were randomly assigned 
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to receive 25 mL/day of three similar olive oils, but with di-
fferences in their phenolic content (from 2.7 mg/ kg to 366 
mg/kg of olive oil), in intervention periods of 3 weeks pre-
ceded by 2 week washout periods. All olive oils increased 
the HDL-cholesterol and the ratio between the reduced 
and oxidized forms of glutathione. In the EUROLIVE study, 
consumption of medium- and high-phenolic content olive 
oil decreased lipid oxidative damage biomarkers such as 
plasma oxidized LDL, uninduced conjugated dienes, and 
hydroxy fatty acids, without changes in F2-isoprostanes. 
But the most important results of the EUROLIVE study 
were that the increase in HDL cholesterol and the decrea-
se in the lipid oxidative damage were linear with the phe-
nolic content of the olive oil consumed. The results of the 
EUROLIVE study provided first level evidence that olive oil 
is more than a MUFA fat.  
Concerning DNA oxidative damage, the urinary excretion 
of 8-oxo-deoxyguanosine (dGuo) is advocated as a bio-
marker of the whole body DNA oxidation, a risk factor for 
cardiovascular and cancer diseases. A protective effect 
of phenolic compounds from VOO has been reported on 
in vivo DNA oxidation both in healthy male subjects and in 
postmenopausal women8. Results of the EUROLIVE stu-
dy, however, show that consumption of 25 mL of olive oil 
per day during 3 weeks reduced DNA oxidation in 182 
healthy males, as measured by the 24 h urinary excretion 
of dGuo, irrespective of the olive oil phenolic content25. 
Differences in the type of population involved (with or 
without oxidative stress) could explain differences among 
results. In this sense, one conclusion of the Consensus 
Report made by the Expert Panel in the International Con-
ference of Olive Oil and Health held in Jaen, Spain, Oc-
tober 20047,26 was that the protective effects on oxidation 
markers in human trials were better displayed in oxidative 
stress conditions.
Inflammation, endothelial function, 
and blood pressure 
Other pathological conditions, present in chronic degene-
rative diseases, such as cardiovascular, cancer, and neu-
rodegenerative, and linked to oxidative stress are inflam-
mation, endothelial dysfunction, hypertension etc. Here 
we will revise the available information related concerning 
the effects of VOO consumption on these conditions.
Although the protective mechanism of oleic acid–rich 
diets on inflammation has been attributed to a decrease 
in the LDL linoleic acid content, oleic acid is not the single 
responsible factor for the anti-inflammatory properties of 
olive oil. Several studies have examined the anti-inflam-
matory and vasculoprotective effect of olive oil phenolic 
Author, year Type of study Subjects   Intervention Biomarkers Effects 
(Reference)
Table I: Randomized controlled studies on the effect of VOO on inflammatory and vasculoprotective markers.
TXB2, thromboxane B2; 6-keto- PGF1α, 6-keto-prostaglandin1α; PRP, platelet-rich plasma; LTB4, leukotriene B4, ICAM-1, intercellular adhesion molecule-1; VCAM-1, 
vascular cell adhesion molecule-1; CHD, coronary heart disease; hsCRP; high sensitivity C reactive protein; IL-6, interleukin 6 ADMA, asymmetric dimethylarginine; 
TNF-α, tumour necrosis factor alpha; IL-1β, interleukin 1β;MIF, macrophage migration inhibitory factor; JNK, c-Jun Nterminal kinase; LPS, lipopolysaccharide.
Visioli et al.
200527 
Oubiña et al. 
200128
Bogani et al. 
200629
Fitó et al. 
200830
Moreno-Luna 
et al. 201231 
Pacheco et al. 
200732
Pérez-Herrera 
et al. 201233
Windmer et 
al. 201334
12 postmenopausal 
women
12 healthy men VOO vs refined olive oil 
(50 mL with potatoes)
VOO vs refined olive oil (intervention 
period, 50 mL/d, 3 weeks; washout 
period 2 weeks with refined olive oil 
ad libitum)
Rich polyphenol-VOO (30 mg/day) 
vs free polyphenol olive oil (2month; 
4-week washout period)
Decrease with the 
phenolic content of 
the olive oil
Decrease with the 
phenolic content of 
the olive oil
No changes
Decrease with the 
phenolic content of 
the olive oil
Decrease with the 
phenolic content of 
the olive oil
Decrease with oils 
containing polyphe-
nols and antioxidants
Decrease with VOO
VOO vs oleic acid-rich sunflower oil Lower in VOO 
Similar 
Similar 
TXB2 in PRP
TXB2 in urine
6-keto-PGF
1α
Plasma LTB4 
Plasma TBX2
hsCRP, IL-6  
Serum ICAM-1 
and 
VCAM-11
ADMA
hs-CRP
2 consecutive 
periods, no washout, 
diets ad libitum
Randomized, 
crossover postprandial
Randomized, crossover
Randomized, crossover
Randomized, crossover, 
postprandial
Randomized, crossover 
postprandial
Randomized, parallel
24 women with high-
normal BP or stage 1 
essential hypertension
Healthy (14) and hyper-
triglyceridemic (14) men
20 obese participants
82 patients with early 
atherosclerosis 
Fat meal with VOO vs refined olive oil, 
after 1 week of each (50 mg/m2 body 
surface)
Breakfast with VOO, sunflower oil 
(SFO) and SFO+canola oil (heated) 
with added polyphenols or artificial 
antioxidants
VOO* and VOO+ EECG (30mL/d, 
4 months)
Serum ICAM-1 
and VCAM-1 
area under curve
TNF-α, IL-1β, 
IL-6, MIF, JNK, 
and LPS
NFĸB and  su-
bunits activators
ICAM-1
White blood cells
28 men with CHD 
Randomized, crossover Hyperlipidemic patients 
(12 men and 10 women)
VOO vs refined olive oil (intervention, 
40 mL/d, 7 weeks; washout period, 
4 weeks with usual diet)
VOO vs oleic acid-rich sunflower oil
Serum TBX2 Decrease with the 
phenolic content of 
the olive oil
43Medicina Balear 2014; 29 (2); 39-46 
María-Isabel Covas et al. Scientific evidence of the benefits of virgin olive oil for human health 
compounds in humans (Table I). In these studies, VOO 
with high phenolic content has been shown to be effective 
in reducing the eicosanoid inflammatory mediators deri-
ved from arachidonic acid, such as thromboxane B2 and 
6-keto-prostaglandin F1α
27-29, as well as other inflammatory 
markers, such as high-sensibility C-reactive protein or in-
terleukin-630,31. A decrease of intracellular adhesion mole-
cule-1 (ICAM-1) and valscular cell adhesion molecule-1 
(VCAM-1) serum levels at postprandial state after VOO 
when compared with refined olive oil ingestion has been 
reported32. Also, the postprandial inflammatory response 
after ingestion of heated oils in obese persons was redu-
ced by the presence of oils with phenolic compounds or 
non natural antioxidants33. In this study33, VOO or a mix 
of sunflower and canola oil artificially enriched with olive 
oil phenolic compounds and other antioxidants, lowered 
the postprandial nuclear factor ĸappa B (NF-ĸB) activa-
tion, increased NF-ĸB inhibitor (IĸB-α), and decreased 
lipopolysaccharide (LPS) plasma concentration), compa-
red with sunflower oil. In sustained consumption studies, 
a decrease in ICAM-1 after VOO, but not after VOO plus 
epigallocatechin-3-galate (EGCG) in early atherosclerosis 
patients has been reported34. However, no differences in 
ICAM-1 or VCAM-1 levels were reported after sustained 
virgin or refined olive oil consumption in coronary heart di-
sease (CHD) patients30. 
Vasomotor, haemostatic, antioxidant, and inflammatory 
activities are involved in endothelial dysfunction, a recent 
focus of intense research in cardiovascular medicine35. 
The effect of VOO reducing oxidative stress and oxidative 
damage, as well as the inflammatory markers has been 
described above. The postprandial prothrombotic profile 
improved in healthy subjects and hypercholesterolemic 
patients after intake of phenol-rich VOO versus a low-
phenolic content olive oil2. Several studies have reported 
beneficial effects of VOO on the endothelial function. An 
improved post-ischemic hyperemia via reduced oxidative 
stress and increased nitric oxide metabolites was repor-
ted after the intake of phenol-rich VOO in comparison with 
a low-phenol olive oil in hypercholesterolemic patients36. 
The effect of VOO phenols on the postprandial endothelial 
function seems to be mediated by the NOS3 Glu298Asp 
polymorphism in patients with metabolic syndrome37. Be-
neficial effects improving the endothelial function have 
been observed after a 4-month diet with polyphenol-rich 
olive oil in patients with early atherosclerosis34. 
Consumption of olive oil reduces blood pressure2. Howe-
ver, phenolic compounds in VOO play also a beneficial 
role. A decrease in systolic (SBP) and diastolic blood 
pressure, with an improvement of endothelial function, has 
been reported after a 2-month diet with rich-polyphenol 
olive oil versus a low polyphenol one, in young women 
with mild hypertension31. In this study31, changes in blood 
pressure and endothelial function were concomitant with 
markers related with vasodilatation, such as an increase 
in nitric oxide and a decrease in serum asymmetric di-
methylarginine, as well as a reduction in oxidized LDL and 
hsCRP. VOO, reduced SBP in hypertensive women and 
stable CHD patients in comparison with high-oleic sun-
flower oil and refined olive oil, respectively38. In a parallel 
study comparing the effect of VOO on blood pressure in 
diabetic patients and healthy individuals, a reduction in 
SBP was observed in both conditions39. 
Mechanisms by which VOO and its 
phenolic compounds can exert their 
benefits in vivo in humans. 
Although there is a huge body of experimental studies 
concerning mechanisms by which VOO and its phenolic 
compounds could exert their beneficial effects, up-to-date 
only two have been reported to occur in vivo in humans: 
1) an increase of the antioxidant content of the LDL, and 
2) a nutrigenomic effect. 
Consumption of VOO increases the antioxidant 
content of the LDL 
In human studies the best results obtained on lipid oxi-
dation markers after VOO consumption are displayed in 
those markers directly associated with LDL. This was one 
of the conclusions of the Consensus Report made by the 
Expert Panel in the International Conference of Olive Oil 
and Health held in Jaen, Spain, October 20047, 26 This 
could be explained on one hand by the fact that ingestion 
of any type of olive oil increases the plasma oleic acid con-
tent of the LDL lipoprotein. After olive oil ingestion, oleic 
acid concentration in LDL increased and those of linoleic 
and arachidonic acid decreased40. As has been referred 
to before, oleate-rich LDL are less susceptible against oxi-
dation than linoleate-rich particles14. On the other hand, 
the total polyphenol content bound to human LDL increa-
se in a dose dependent manner with the phenolic content 
of the olive oil administered10. OHTyr and Tyr metabolites, 
glucuronides and sulfates, have been reported to bind 
human LDL after VOO ingestion, but were not detected 
after refined olive oil ingestion40. An inverse relationship 
between plasma levels of oxidized LDL and the content 
of phenols bound to LDL has been reported40. Phenolic 
compounds which can bind LDL are likely to perform their 
peroxyl scavenging activity in the arterial intima, where full 
LDL oxidation occurs17.  
Nutrigenomic effect of VOO and its phenolic 
compounds 
Nutrigenomics embrace all “omics” fields, such as geno-
mics, transcriptomics, proteomics, and metabonomics 
with the aim of understanding and characterizing how 
nutrients and/or food act at molecular level. Here we will 
focuse in the transcriptomic data available from human 
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studies, and particularly in those studies in which different 
types of olive oils have been tested with the same dietary 
pattern as background. Several studies have examined 
the transcriptomic profile after VOO, in comparison with 
low phenolic content olive oil, both at postprandial state 
and after sustained consumption41. A breakfast based 
on VOO, high in polyphenols (398 ppm), was able to 
postprandially repress the expression of proinflammatory 
genes when compared with a common olive oil based 
breakfast (low in polyphenols, 70 ppm) in metabolic syn-
drome individuals. Microarray results showed 19 upre-
gulated and 79 downregulated genes, linked to obesity, 
dyslipemia, and type 2 diabetes mellitus, after the intake 
of VOO41. A VOO enriched with its own phenolic com-
pounds enhanced the postprandial expression of cho-
lesterol efflux related genes in vivo in humans versus 
an standard VOO. In our pre- and stage I hypertensive 
patients, we observed an increase in ATP binding cas-
sette transporter-A1(ABCA1), scavenger receptor class 
B type1 (SR-B1), peroxisome proliferator-activated re-
ceptors and binding protein (PPARBP, PPARα, PPARγ, 
PPARδ) and CD36 gene expression in white blood cells 
at postprandial after high polyphenol VOO when compa-
red with standard VOO22. 
Also within the frame of a Mediterranean diet (MeD), in a 
parallel, controlled, 3-month intervention trial, 90 healthy 
volunteers were randomized to three intervention dietary 
patterns: I) MeD supplemented with rich-polyphenol VOO 
(328mg/kg); II) MeD supplemented with washed VOO (low 
in polyphenols: 55 mg/kg); and III) habitual diet (control 
group). Only after the MeD supplemented with rich-po-
lyphenol VOO there was a significant decrease, versus the 
control group, in the expression of inflammatory genes: in-
terferon gamma (IFNγ), Rho GTPase activating protein 15 
(ARHGAP15), and interleukin 7 receptor (IL7R); and oxida-
tive stress: adrenergic b-2 receptor (ADRB2). Changes in 
gene expression after the MeD supplemented with VOO 
were concomitant with decreases in lipid oxidative dama-
ge and systemic inflammation markers42. In the frame of 
the PREDIMED study, two studies have reported differen-
ces when an enrichment of the MeD with VOO occurs. 
In the first43, a 3-month intervention with VOO-enriched 
MeD prevented the increase in cyclooxigenase-2 (COX2) 
and LDL receptor-related protein (LRP1) genes, as well 
as reduced the expression of monocyte chemoattractant 
protein (MCP1) gene, compared with a MeD enriched 
with nuts or with a low-fat diet. In the second, study44, 
we compared 3-month changes in the whole genome of 
peripheral blood mononuclear cells. Results of functional 
annotation analyses showed that from 18 cardiovascular 
canonical pathways, 9 were modulated by a MeD enri-
ched with VOO and 4 when the MeD was enriched with 
nuts44. In a sub-study of the EUROLIVE study, we pro-
posed for the first time an integrated scheme for the in 
vivo downregulation of the CD40/CD40L system and its 
downstream products promoted by the consumption of 
VOO45. Our results showed a decrease in the expression 
of pro-atherogenic genes: CD40 antigen ligand (CD40L), 
interleukin 23A (IL23A), ADRB2, oxidized LDL (lectin-like) 
receptor 1 (OLR1), interleukin-8 receptor-a (IL8RA), and 
IL7R) after consumption of VOO high in polyphenols when 
compared with the refined olive oil, low in polyphenols. 
The decrease in these genes was concomitant with the 
decreasing trend of interlinked ones such as vascular en-
dothelial growth factor (VEGF), ICAM-1, and MCP1. In this 
study45, the reduction in LDL oxidation and the increase 
in antioxidant polyphenols in LDL promoted by the regular 
dietary intake of phenolic compound-rich VOO, were as-
sociated with a down regulation in the expression of genes 
related with the CD40/CD40L pathway. Due to all referred 
above, VOO and its phenolic compounds can modulate 
the expression of atherosclerosis related genes towards a 
protective mode in vivo in humans. 
Conclusions 
We have scientific data providing level I evidence that 
VOO can promote additional benefits to those of provided 
by other vegetable oils on risk factors for cardiovascular 
disease such as lipids and lipid oxidation, inflammation, 
endothelial dysfunction and systolic blood pressure. At 
present, the known mechanisms by which VOO can exert 
these beneficial effects in humans arethe increase in the 
antioxidant content of LDL, and a nutrigenomic effect, 
modulating towards a protective mode the expression of 
atherosclerosis-related genes. 
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